Novartis is an international pharmaceutical company headquartered in Basel, Switzerland. The company’s subdivisions, factories and research centres are located in different countries throughout the world and incorporate more than 110 thousand employees – representatives of 142 nationalities. The company’s pharmaceutical portfolio includes over 50 key products presented in the global market. As of 2020, one of the Group of Companies’ divisions – Sandoz makes the top three leaders among generic companies and represents over 100 OTC, prescription and specialised medicines in Russia. 

Since 2010, Novartis Group of Companies has been implementing a strategic investment programme in our country, which includes organisation of local production, scientific research and development in partnership with the leading universities and scientific institutions, and improvement of the healthcare system. All the Group’s divisions are currently presented in Russia – innovative products, generic pharmaceuticals and biosimilars, eyesight care, as well as own pharmaceutical production sites. 

In 2015, the construction of Novartis Neva pharmaceutical plant in St. Petersburg was completed. In 2017, the plant commenced its commercial production, and in autumn 2018, the first batch of officinal medicines was released. Novartis Neva was designed in compliance with all the GMP rules, and currently, the plant produces an integrated portfolio of innovative medicines and generics that meet the highest international quality and safety standards. 

Novartis traditionally pays special attention to creating a comfortable working environment and developing a corporate culture that allows each employee to unleash his/her potential. In January 2021, Novartis Pharma LLC and Sandoz JSC, divisions of Novartis Group of Companies, obtained official certification of the Top Employers Institute for the exceptional conditions for employees in Russia. 

Participation of Novartis in the VI All-Russian GMP Conference will enrich the event agenda with the company’s unique expertise. 

295418-1/NVS/DIG/09.21/0